Table 1 Baseline risk factors for Cardiotoxicity (ESC Guidelines)

• Heart failure (with either preserved or reduced ejection fraction)

Age (paediatric population < 18 years; >50 years for trastuzumab; >65 years for anthracyclines)

• Asymptomatic LV dysfunction (LVEF <50% or high natriuretic peptide^a)

Family history of premature CV disease (<50 years)

• Evidence of CAD (previous myocardial infarction, angina, PCI or CABG, myocardial ischaemia)

Arterial hypertension

Diabetes mellitus

Hypercholesterolaemia

• Moderate and severe VHD with LVH or LV impairment

• Hypertensive heart disease with LV hypertrophy

• Hypertrophic cardiomyopathy

• Dilated cardiomyopathy

• Restrictive cardiomyopathy

• Cardiac sarcoidosis with myocardial involvement

• Significant cardiac arrhythmias (e.g.AF, ventricular tachyarrhythmias)

Previous cardiotoxic cancer treatment

Lifestyle risk factors

• Prior anthracycline use

• Smoking

• Prior radiotherapy to chest or mediastinum

• High alcohol intake

• Obesity

• Sedentary habit